Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions
Launched by M.D. ANDERSON CANCER CENTER · Jul 16, 2007
Trial Information
Current as of July 07, 2025
Completed
Keywords
ClinConnect Summary
All tissue and cells are made of tiny particles that give off small amounts of light. This light is called fluorescence. Scientists have learned that cancerous cells and normal cells give off different amounts and different types of fluorescence. Scientists need to better understand whether fluorescence from the oral cavity (mouth) can be used to tell which cells are abnormal. This information can help doctors detect pre-cancers.
In order to better understand fluorescence, researchers at the Optical Spectroscopy and Imaging Lab, Department of Bioengineering, Rice University have developed ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subjects with lesions of the oral cavity mucosa or suspicious for malignancy or premalignancy.
- • 2. Subjects with the ability and willingness to sign an informed consent and authorization.
- • 3. Subjects who develop new lesions or alterations in long-standing lesions are eligible, but not required, for re-examination with informed consent.
- Exclusion Criteria:
- • 1. Persons who are medically unfit to undergo superficial punch biopsies of oral mucosa.
- • 2. Persons under the age of 18.
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Ann M. Gillenwater, MD
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials